Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
Rhea-AI Summary
Apyx Medical (NASDAQ: APYX) will release its financial results for the second quarter of fiscal year 2026 after market close on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. Eastern Time the same day to discuss the results and hold a Q&A session.
Investors can join by phone using access code 53282 at 800-717-1738 (U.S.) or 646-307-1865 (international), or via a live webcast available through the company’s Investor Relations website, where a replay will be archived.
Positive
- None.
Negative
- None.
News Market Reaction – APYX
In the Jul 23 session, APYX declined 2.05%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Earnings date | Neutral | -0.8% | First-quarter fiscal 2026 results release and conference call were scheduled for May 7 |
| Feb 25 | Earnings date | Neutral | -3.4% | Fourth-quarter fiscal 2025 results release and conference call were scheduled for March 10 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Both tag-matched earnings-date announcements were followed by negative 24-hour moves, averaging -2.08%.
Key Terms
fda-cleared regulatory
electrosurgical medical
oem agreements financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the second quarter of fiscal year 2026 will be released after markets close on Thursday, August 6th.
Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 6th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 53282. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference.
About Apyx Medical Corporation:
Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
